Options
2017
Journal Article
Title
OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors
Title Supplement
Opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial
Abstract